SEARCH

SEARCH BY CITATION

References

  • 1
    Vigliani R. Galen's oncology. Pathologica 1995; 87: 57790.
  • 2
    Brown JR,DuBois RN. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol 2005; 23: 284055.
  • 3
    Balkwill F,Charles KA,Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005; 7: 21117.
  • 4
    Sinicrope FA. Targeting cyclooxygenase-2 for prevention and therapy of colorectal cancer. Mol Carcinog 2006; 45: 44754.
  • 5
    Szlosarek PW,Grimshaw MJ,Kulbe H,Wilson JL,Wilbanks GD,Burke F,Balkwill FR. Expression and regulation of tumour necrosis factor α in normal and malignant ovarian epithelium. Mol Cancer Ther 2006; 5: 38290.
  • 6
    Delhalle S,Deregowski V,Benoit V,Merville MP,Bours V. NF-κB-dependent MnSOD expression protects adenocarcinoma cells from TNF-α-induced apoptosis. Oncogene 2002; 21: 391724.
  • 7
    Wu G,Morris SM,Jr. Arginine metabolism: nitric oxide and beyond. Biochem J 1998; 336: 117.
  • 8
    Lala PK,Chakraborty C. Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol 2001; 2: 14956.
  • 9
    Gerner EW,Meyskens FL. Polyamines and cancer: old molecules, new understanding. Nat Rev Cancer 2004; 4: 78192.
  • 10
    Benard J,Da Silva J,De Blois MC,Boyer P,Duvillard P,Chiric E,Riou G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985; 45: 49709.
  • 11
    Hamilton TC,Young RC,McKoy WM,Grotzinger KR,Green JA,Chu EW,Whang-Peng J,Rogan AM,Green WR,Ozols RF. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res 1983; 43: 537989.
  • 12
    Langdon SP,Lawrie SS,Hay FG,Hawkes MM,McDonald A,Hayward IP,Schol DJ,Hilgers J,Leonard RC,Smyth JF. Characterization and properties of nine human ovarian adenocarcinoma cell lines. Cancer Res 1988; 48: 616672.
  • 13
    Kruk PA,Maines-Bandiera SL,Auersperg N. A simplified method to culture human ovarian surface epithelium. Lab Invest 1990; 63: 1326.
  • 14
    Grimshaw MJ,Mason RM. Modulation of bovine articular chondrocyte gene expression in vitro by oxygen tension. Osteoarthritis. Cartilage 2001; 9: 35764.
  • 15
    Scotton C,Burke F. Northern analysis, RT-PCR, RNase protection, cDNA array systems, and in situ hybridisation to detect cytokine mRNA. In: BalkwillF, ed. Cytokine molecular biology. The Bath Press, Avon, 2000.
  • 16
    Koh E,Noh SH,Lee YD,Lee HY,Han JW,Lee HW,Hong S. Differential expression of nitric oxide synthase in human stomach cancer. Cancer Lett 1999; 146: 17380.
  • 17
    Ensor CM,Holtsberg FW,Bomalaski JS,Clark MA. Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002; 62: 544350.
  • 18
    Tang SW,Chang WH,Chao YW,Lin CY,Chen HF,Lai YH,Zhan BW,Su YC,Jane SW,Chen YC,Hsu CI,Lin WC et al. Identification of differentially expressed genes in clear cell renal cell carcinoma by analysis of full-length enriched cDNA library. J Biomed Sci 2006; 13: 23340.
  • 19
    Szlosarek PW,Charles KA,Balkwill FR. Tumour necrosis factor-α as a tumour promoter. Eur J Cancer 2006; 42: 74550.
  • 20
    Satriano J. Arginine pathways and the inflammatory response: interregulation of nitric oxide and polyamines: review article. Amino Acids 2004; 26: 3219.
  • 21
    Subbarayan V,Sabichi AL,Llansa N,Lippman SM,Menter DG. Differential expression of cyclooxygenase-2 and its regulation by tumour necrosis factor-α in normal and malignant prostate cells. Cancer Res 2001; 61: 27206.
  • 22
    Brasse-Lagnel C,Lavoinne A,Fairand A,Vavasseur K,Husson A. IL-1β stimulates argininosuccinate synthetase gene expression through NF-κB in Caco-2 cells. Biochimie 2005; 87: 4039.
  • 23
    Brasse-Lagnel C,Fairand A,Lavoinne A,Husson A. Glutamine stimulates argininosuccinate synthetase gene expression through cytosolic O-glycosylation of Sp1 in Caco-2 cells. J Biol Chem 2003; 278: 5250410.
  • 24
    Nussler AK,Liu ZZ,Hatakeyama K,Geller DA,Billiar TR,Morris SM,Jr. A cohort of supporting metabolic enzymes is coinduced with nitric oxide synthase in human tumour cell lines. Cancer Lett 1996; 103: 7984.
  • 25
    Barcelo-Batllori S,Andre M,Servis C,Levy N,Takikawa O,Michetti P,Reymond M,Felley-Bosco E. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: implications for inflammatory bowel diseases. Proteomics 2002; 2: 55160.
  • 26
    Thomsen LL,Sargent JM,Williamson CJ,Elgie AW. Nitric oxide synthase activity in fresh cells from ovarian tumour tissue: relationship of enzyme activity with clinical parameters of patients with ovarian cancer. Biochem Pharmacol 1998; 56: 136570.
  • 27
    Klimp AH,Hollema H,Kempinga C,van der Zee AG,de Vries EG,Daemen T. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumours and tumour-associated macrophages. Cancer Res 2001; 61: 73059.
  • 28
    Raspollini MR,Amunni G,Villanucci A,Boddi V,Baroni G,Taddei A,Taddei GL. Expression of inducible nitric oxide synthase and cyclooxygenase-2 in ovarian cancer: correlation with clinical outcome. Gynecol Oncol 2004; 93: 80612.
  • 29
    Lawton F,Griffin M,Slack J,Blackledge G. Urinary polyamine excretion patterns in patients with epithelial ovarian cancer. Gynecol Obstet Invest 1989; 28: 21214.
  • 30
    Lawton FG,Griffin M,Slack JA,Blackledge G. Predicting response to chemotherapy for patients with epithelial ovarian cancer using urinary polyamine excretion patterns. Br J Cancer 1990; 62: 6924.
  • 31
    Brasse-Lagnel C,Lavoinne A,Fairand A,Vavasseur K,Deniel N,Husson A. Biphasic effect of IL-1β on the activity of argininosuccinate synthetase in Caco-2 cells. Involvement of nitric oxide production. Biochimie 2006; 88: 60712.
  • 32
    Hao G,Xie L,Gross SS. Argininosuccinate synthetase is reversibly inactivated by S-nitrosylation in vitro and in vivo. J Biol Chem 2004; 279: 36192200.
  • 33
    Jacobsen LC,Theilgaard-Monch K,Christensen EI,Borregaard N. Arginase 1 is expressed in myelocytes/metamyelocytes and localized in gelatinase granules of human neutrophils. Blood, in press.
  • 34
    Irie K,Tsukahara F,Fujii E,Uchida Y,Yoshioka T,He WR,Shitashige M,Murota S,Muraki T. Cationic amino acid transporter-2 mRNA induction by tumor necrosis factor-α in vascular endothelial cells. Eur J Pharmacol 1997; 339: 28993.
  • 35
    Dillon BJ,Prieto VG,Curley SA,Ensor CM,Holtsberg FW,Bomalaski JS,Clark MA. Incidence and distribution of argininosuccinate synthetase deficiency in human cancers: a method for identifying cancers sensitive to arginine deprivation. Cancer 2004; 100: 82633.
  • 36
    Izzo F,Marra P,Beneduce G,Castello G,Vallone P,De Rosa V,Cremona F,Ensor CM,Holtsberg FW,Bomalaski JS,Clark MA,Ng C et al. Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: results from phase I/II studies. J Clin Oncol 2004; 22: 181522.
  • 37
    Ascierto PA,Scala S,Castello G,Daponte A,Simeone E,Ottaiano A,Beneduce G,De Rosa V,Izzo F,Melucci MT,Ensor CM,Prestayko AW et al. Pegylated arginine deiminase treatment of patients with metastatic melanoma: results from phase I and II studies. J Clin Oncol 2005; 23: 766068.
  • 38
    Szlosarek PW,Klabatsa A,Pallaska A,Sheaff M,Smith P,Crook T,Grimshaw MJ,Steele JP,Rudd RM,Balkwill FR,Fennell DA. In vivo loss of expression of argininosuccinate synthetase in malignant mesothelioma is a biomarker for susceptibility to arginine depletion. Clin Cancer Res 2006; 12: 712631.